Efavirenz, lamivudine, tenofovir disoproxil
Sold as Tenarenz, Eflaten, Hetlatef, Teliefawin, Tritlef, Arion, Anchoa, Virlaten, Elteno, Trilameften, Lanforenz, Latenef, Vonaday, Trieta, Trilef, Eflotela, Enlativ, Zeltedvir
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 12
- Registrations
- 18
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pharmacare limited û woodmead | Tenarenz | Not stated | 441051 | S4 | None |
| Viatris Healthcare (Pty) LtdCertificate held by Mylan | Eflaten, Eflotela | 300mg, 300 mg, 300 mg, 400 mg, 600mg | 450171, 570785 | S4 | PIPIL |
| Hetero Drugs South Africa (Pty) Ltd | Hetlatef, Enlativ, Zeltedvir | Not stated | 480083, 570853, 570854.853 | S4 | None |
| Zentiva South Africa (Pty) Ltd | Teliefawin | Not stated | 480087 | S4 | None |
| Aurobindo Pharma (Pty) LtdCancelled | Tritlef | 600 mg/300 mg/300 mg | 480340 | Not determined | None |
| Novagen Pharma (Pty) LtdCancelled | Arion | Not stated | 480347 | S4 | None |
| Unimed Healthcare (Pty) Ltd | Anchoa | Not stated | 480348 | S4 | None |
| Sandoz South Africa (Pty) Ltd | Virlaten | Not stated | 490055 | S4 | None |
| Macleods Pharmaceuticals SA (Pty) Ltd | Elteno | Not stated | 490224 | S4 | None |
| Specpharm (Pty) LtdCancelled | Trilameften | Not stated | 490677 | S4 | None |
| Cipla Medpro (Pty) Ltd2 of 4 cancelled | Lanforenz, Latenef, Trieta, Trilef | 400mg, 300 mg, 300 mg | 500317, 500318, 560482, 560483.482 | S4 | PIPIL |
| Emcure- Pharmaceutical South Africa (Pty) LtdCancelled | Vonaday | Not stated | 540208 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Tenarenz EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 44105144/20.2.8/1051 | Registered | S4 | None |
| Eflaten EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | 300mg. 300mg. 600mgTablet | 45017145/20.2.8/0171Approved 6 June 2012 | Registered | S4 | PIPIL |
| Hetlatef EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 48008348/20.2.8/0083 | Registered | S4 | None |
| Teliefawin EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 48008748/20.2.8/0087 | Registered | S4 | None |
| Tritlef 600 mg/300 mg/300 MG EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE EQUIVALENT TO TENOFOVIR DISOPROXIL 245,0 mg | 600 mg/300 mg/300 mg | 48034048/20.2.8/0340 | Cancelled | Not determined | None |
| Arion EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 48034748/20.2.8/0347 | Cancelled | S4 | None |
| Anchoa EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 48034848/20.2.8/0348 | Registered | S4 | None |
| Virlaten EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 49005549/20.2.8/0055 | Registered | S4 | None |
| Elteno EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 49022449/20.2.8/0224 | Registered | S4 | None |
| Trilameften EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 49067749/20.2.8/0677 | Cancelled | S4 | None |
| Lanforenz EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 50031750/20.2.8/0317 | Cancelled | S4 | None |
| Latenef EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 50031850/20.2.8/0318 | Cancelled | S4 | None |
| Vonaday EACH TABLET CONTAINS EFAVIRENZ 600,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg | Not listed | 54020854/20.2.8/0208 | Cancelled | S4 | None |
| Trieta EACH TABLET CONTAINS EFAVIRENZ 400,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL EQUIVALENT TO TENOFOVIR DISOPROXIL 245,0 mg | 400mg, 300 mg, 300 mgTablet | 56048256/20.2.8/0482Approved 2 May 2023 | Registered | Not determined | PIPIL |
| Trilef EACH TABLET CONTAINS EFAVIRENZ 400,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL EQUIVALENT TO TENOFOVIR DISOPROXIL 245,0 mg | 400mg, 300 mg, 300 mgTablet | 560483.48256/20.2.8/0483.482Approved 2 May 2023 | Registered | Not determined | PIPIL |
| Eflotela EACH TABLET CONTAINS TENOFOVIR DISOPROXIL FUMARATE 300,0 mg LAMIVUDINE 300,0 mg EFAVIRENZ 400,0 mg | 300 mg, 300 mg, 400 mgTablets | 57078557/20.2.8/0785Approved 26 September 2023 | Registered | S4 | PIPIL |
| Enlativ Each Tablet contains: Efavirenz 400,0 mg; Lamivudine 300,0 mg, Tenofovir Disoproxil Fumarate equivalent to Tenofovir Disoproxil 300,0 mg | Not listed | 57085357/20.2.8/0853 | Registered | Not determined | None |
| Zeltedvir Each Tablet contains: Efavirenz 400,0 mg; Lamivudine 300,0 mg, Tenofovir Disoproxil Fumarate equivalent to Tenofovir Disoproxil 300,0 mg | Not listed | 570854.85357/20.2.8/0854.853 | Registered | Not determined | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence medium.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Efavirenz, lamivudine, tenofovir disoproxil fumarate
S4: Efavirenz
Consolidated Schedules 06 July 2026, line 6159
S4: Lamivudine
Consolidated Schedules 06 July 2026, line 6850
S4: Tenofovir
Consolidated Schedules 06 July 2026, line 8130
Pharmacological class: Antiviral agents. (class 20.2.8)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Eflaten, Viatris Healthcare (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.